FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040097601> ?p ?o ?g. }

• W3040097601 endingPage "7820" @default.
• W3040097601 startingPage "7812" @default.
• W3040097601 abstract "Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific membrane antigen (PSMA) in vivo, which is the target molecule of 177Lu-PSMA-617 (Lu-PSMA) therapy. However, the correlation of PSMA expression and overall survival (OS) in patients treated with Lu-PSMA therapy is currently unclear; especially with regard to coexistence of high and low PSMA expressing metastases. To this end, this retrospective single arm study elucidates the correlation of PSMA expression and overall survival in patients treated with Lu-PSMA therapy. Additionally, PET based criteria to define low PSMA expression were explored. Methods: Eighty-five patients referred to Lu-PSMA therapy were included in the analysis. Pretherapeutic 68Ga-PSMA-PET-CT scans were available for all patients. SUVmax of the highest PSMA expressing metastasis (PSMAmax), SUVmax of the lowest PSMA expressing metastasis (PSMAmin), and average SUVmax of all metastases (PSMAaverage) amongst other PET parameters were measured for each patient. A log-rank cutoff-finder was used to determine low (lowPSMAaverage) and high (highPSMAaverage) average PSMA expression as well as low (lowPSMAmin) and high (highPSMAmin) minimal PSMA expression. Results: PSMAaverage was a significant prognosticator of overall survival in contrast to PSMAmax (HR: 0.959; p = 0.047 vs. HR: 0.992; p = 0.231). Optimal log rank cut-offs were: PSMAaverage = 14.3; PSMAmin = 10.2. Patients with low average PSMA expression (lowPSMAaverage) had significantly shorter survival compared to those with high average expression (highPSMAaverage) (5.3 vs. 15.1 months; p < 0.001; HR: 3.738, 95%CI = 1.953-7.154; p < 0.001). Patients with low PSMA expressing metastases (lowPSMAmin) had shorter survival compared to those without a low PSMA expressing metastasis (highPSMAmin) (p = 0.003; 7.9 months vs. 21.3; HR: 4.303, 95%CI = 1.521-12.178; p = 0.006). Patients that were classified as highPSMAaverage but with lowPSMAmin had an intermediate overall survival (11.4 months; longer compared to lowPSMAaverage, 5.3 months, p = 0.002; but shorter compared to highPSMAmin, 21.3 months, p = 0.02). Conclusion: Low average PSMA expression is a negative prognosticator of overall survival. Absence of low PSMA expressing metastases is associated with best overall survival and the maximum PSMA expression seems not suited to prognosticate overall survival. Low PSMA expression might therefore be a negative prognosticator for the outcome of patients treated with Lu-PSMA therapy. Future studies are warranted to elucidate the degree of low PSMA expression tolerable for Lu-PSMA therapy." @default.
• W3040097601 created "2020-07-10" @default.
• W3040097601 creator A5000148457 @default.
• W3040097601 creator A5006830341 @default.
• W3040097601 creator A5017131649 @default.
• W3040097601 creator A5017161970 @default.
• W3040097601 creator A5028012490 @default.
• W3040097601 creator A5032460328 @default.
• W3040097601 creator A5033302235 @default.
• W3040097601 creator A5071178428 @default.
• W3040097601 creator A5082002105 @default.
• W3040097601 date "2020-01-01" @default.
• W3040097601 modified "2023-10-08" @default.
• W3040097601 title "Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving ¹⁷⁷Lu-PSMA-617 Radioligand Therapy" @default.
• W3040097601 cites W1987012261 @default.
• W3040097601 cites W2066520132 @default.
• W3040097601 cites W2126812800 @default.
• W3040097601 cites W2130933657 @default.
• W3040097601 cites W2150575159 @default.
• W3040097601 cites W2168901797 @default.
• W3040097601 cites W2341926107 @default.
• W3040097601 cites W2461069211 @default.
• W3040097601 cites W2515351720 @default.
• W3040097601 cites W2532226140 @default.
• W3040097601 cites W2562613933 @default.
• W3040097601 cites W2763185726 @default.
• W3040097601 cites W2763982071 @default.
• W3040097601 cites W2768513671 @default.
• W3040097601 cites W2780781461 @default.
• W3040097601 cites W2787956080 @default.
• W3040097601 cites W2799931007 @default.
• W3040097601 cites W2841858285 @default.
• W3040097601 cites W2895593497 @default.
• W3040097601 cites W2896060946 @default.
• W3040097601 cites W2903807227 @default.
• W3040097601 cites W2937444132 @default.
• W3040097601 cites W2945708305 @default.
• W3040097601 cites W2969742213 @default.
• W3040097601 cites W2972661946 @default.
• W3040097601 cites W2982033774 @default.
• W3040097601 cites W2988034537 @default.
• W3040097601 cites W3010388685 @default.
• W3040097601 cites W3015253420 @default.
• W3040097601 cites W3019914727 @default.
• W3040097601 doi "https://doi.org/10.7150/thno.47251" @default.
• W3040097601 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7359095" @default.
• W3040097601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32685021" @default.
• W3040097601 hasPublicationYear "2020" @default.
• W3040097601 type Work @default.
• W3040097601 sameAs 3040097601 @default.
• W3040097601 citedByCount "65" @default.
• W3040097601 countsByYear W30400976012020 @default.
• W3040097601 countsByYear W30400976012021 @default.
• W3040097601 countsByYear W30400976012022 @default.
• W3040097601 countsByYear W30400976012023 @default.
• W3040097601 crossrefType "journal-article" @default.
• W3040097601 hasAuthorship W3040097601A5000148457 @default.
• W3040097601 hasAuthorship W3040097601A5006830341 @default.
• W3040097601 hasAuthorship W3040097601A5017131649 @default.
• W3040097601 hasAuthorship W3040097601A5017161970 @default.
• W3040097601 hasAuthorship W3040097601A5028012490 @default.
• W3040097601 hasAuthorship W3040097601A5032460328 @default.
• W3040097601 hasAuthorship W3040097601A5033302235 @default.
• W3040097601 hasAuthorship W3040097601A5071178428 @default.
• W3040097601 hasAuthorship W3040097601A5082002105 @default.
• W3040097601 hasBestOaLocation W30400976011 @default.
• W3040097601 hasConcept C121608353 @default.
• W3040097601 hasConcept C126322002 @default.
• W3040097601 hasConcept C143998085 @default.
• W3040097601 hasConcept C144237770 @default.
• W3040097601 hasConcept C148220186 @default.
• W3040097601 hasConcept C170493617 @default.
• W3040097601 hasConcept C20417620 @default.
• W3040097601 hasConcept C2780192828 @default.
• W3040097601 hasConcept C33923547 @default.
• W3040097601 hasConcept C502942594 @default.
• W3040097601 hasConcept C67847695 @default.
• W3040097601 hasConcept C71924100 @default.
• W3040097601 hasConceptScore W3040097601C121608353 @default.
• W3040097601 hasConceptScore W3040097601C126322002 @default.
• W3040097601 hasConceptScore W3040097601C143998085 @default.
• W3040097601 hasConceptScore W3040097601C144237770 @default.
• W3040097601 hasConceptScore W3040097601C148220186 @default.
• W3040097601 hasConceptScore W3040097601C170493617 @default.
• W3040097601 hasConceptScore W3040097601C20417620 @default.
• W3040097601 hasConceptScore W3040097601C2780192828 @default.
• W3040097601 hasConceptScore W3040097601C33923547 @default.
• W3040097601 hasConceptScore W3040097601C502942594 @default.
• W3040097601 hasConceptScore W3040097601C67847695 @default.
• W3040097601 hasConceptScore W3040097601C71924100 @default.
• W3040097601 hasIssue "17" @default.
• W3040097601 hasLocation W30400976011 @default.
• W3040097601 hasLocation W30400976012 @default.
• W3040097601 hasLocation W30400976013 @default.
• W3040097601 hasOpenAccess W3040097601 @default.
• W3040097601 hasPrimaryLocation W30400976011 @default.
• W3040097601 hasRelatedWork W2524354109 @default.
• W3040097601 hasRelatedWork W2525124727 @default.

• next